ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

1 Stock Under $50 with Exciting Potential and 2 to Ignore

KRT Cover Image

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. Keeping that in mind, here is one stock under $50 with massive upside potential and two best left ignored.

Two Stocks Under $50 to Sell:

GXO Logistics (GXO)

Share Price: $37.79

With notable customers such as Nike and Apple, GXO (NYSE: GXO) manages outsourced supply chains and warehousing for various companies.

Why Are We Hesitant About GXO?

  1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
  2. Earnings per share were flat over the last two years and fell short of the peer group average
  3. 6× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly

GXO Logistics is trading at $37.79 per share, or 12.5x forward price-to-earnings. To fully understand why you should be careful with GXO, check out our full research report (it’s free).

Royalty Pharma (RPRX)

Share Price: $33.86

Founded in 1996, Royalty Pharma (NASDAQ: RPRX) acquires pharmaceutical royalties and funds late-stage clinical trials, offering a unique revenue model centered on financing innovative drug development.

Why Does RPRX Worry Us?

  1. Sales stagnated over the last two years and signal the need for new growth strategies
  2. Revenue base of $2.26 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
  3. Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 18.1 percentage points

Royalty Pharma’s stock price of $33.86 implies a valuation ratio of 7x forward price-to-earnings. Check out our free in-depth research report to learn more about why RPRX doesn’t pass our bar.

One Stock Under $50 to Watch:

Karat Packaging (KRT)

Share Price: $29.20

Founded as Lollicup, Karat Packaging (NASDAQ: KRT) distributes and manufactures environmentally-friendly disposable foodservice packaging solutions.

Why Do We Like KRT?

  1. Earnings growth has massively outpaced its peers over the last three years as its EPS has compounded at 27.3% annually
  2. Free cash flow margin expanded by 18.5 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
  3. ROIC punches in at 17.3%, illustrating management’s expertise in identifying profitable investments

At $29.20 per share, Karat Packaging trades at 8.9x forward EV-to-EBITDA. Is now the time to initiate a position? See for yourself in our full research report, it’s free.

Stocks We Like Even More

The Trump trade may have passed, but rates are still dropping and inflation is still cooling. Opportunities are ripe for those ready to act - and we’re here to help you pick them.

Get started by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.